Premium
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-05-22 | Mr. Brenton L. SaundersCEO & Chairman | -2,89k | 45,95k | Sale to Issuer | 15,92 | 425,67k | -0,67% |
| 2026-05-22 | Mr. Brenton L. SaundersCEO & Chairman | 4,45k | 70,80k | Derivative Exercise and Retained Stock | 15,92 | 425,67k | 1,06% |
| 2026-05-19 | Ms. Karen L. LingIndependent Director | 20,34k | 329,48k | Derivative Exercise and Retained Stock | 16,20 | 41,68k | 95,31% |
| 2026-05-05 | Mr. Osama A. EldessoukyExec. VP & CFO | 61,06k | 976,99k | Derivative Exercise and Retained Stock | 16,00 | 201,00k | 43,64% |
| 2026-05-05 | Dr. Yehia HashadExec. VP of Research & Development and Chief Medical officer | 21,06k | 336,93k | Derivative Exercise and Retained Stock | 16,00 | 107,52k | 24,35% |
| 2026-05-05 | Mr. Frederick J. MunschSenior VP, Controller & CAO | 13,55k | 216,78k | Derivative Exercise and Retained Stock | 16,00 | 52,94k | 34,40% |
| 2026-05-05 | Mr. Luc BonnefoyPresident of Surgical | 9,25k | 148,03k | Derivative Exercise and Retained Stock | 16,00 | 34,66k | 36,41% |
| 2026-05-05 | Mr. Thomas J. AppioInitié | 27,58k | 441,33k | Derivative Exercise and Retained Stock | 16,00 | 27,58k | - |
| 2026-05-05 | Mr. Osama A. EldessoukyExec. VP & CFO | -63,94k | 1,02M | Sale to Issuer | 16,00 | 343,19k | -15,70% |
| 2026-05-05 | Dr. Yehia HashadExec. VP of Research & Development and Chief Medical officer | -13,66k | 218,62k | Sale to Issuer | 16,00 | 166,38k | -7,59% |
| 2026-05-05 | Mr. Frederick J. MunschSenior VP, Controller & CAO | -8,67k | 138,77k | Sale to Issuer | 16,00 | 89,64k | -8,82% |
| 2026-05-05 | Mr. Luc BonnefoyPresident of Surgical | -11,97k | 191,52k | Sale to Issuer | 16,00 | 88,03k | -11,97% |
| 2026-04-24 | Mr. Andrew J. StewartPresident of Global Pharmaceuticals & International Consumer | -4,22k | 66,70k | Sale to Issuer | 15,82 | 32,52k | -11,48% |
| 2026-04-24 | Mr. A. Robert D. BaileyExec. VP & Chief Legal Officer | -15,81k | 250,05k | Sale to Issuer | 15,82 | 125,30k | -11,20% |
| 2026-04-24 | Mr. A. Robert D. BaileyExec. VP & Chief Legal Officer | 24,36k | 385,39k | Derivative Exercise and Retained Stock | 15,82 | 125,30k | 24,13% |
| 2026-04-24 | Mr. A. Robert D. BaileyExec. VP & Chief Legal Officer | -15,81k | 0,00 | Derivative Exercise and Sale | 15,82 | 125,30k | - |
| 2026-04-24 | Mr. Andrew J. StewartPresident of Global Pharmaceuticals & International Consumer | 11,05k | 174,81k | Derivative Exercise and Retained Stock | 15,82 | 32,51k | 51,48% |
| 2026-04-24 | Mr. Andrew J. StewartPresident of Global Pharmaceuticals & International Consumer | -4,22k | 66,70k | Vente | 15,82 | 32,51k | -11,48% |
| 2026-03-06 | Mr. A. Robert D. BaileyExec. VP & Chief Legal Officer | 14,60k | 250,33k | Achat | 17,15 | 100,94k | 16,91% |
| 2026-03-06 | Mr. Osama A. EldessoukyExec. VP & CFO | 4,00k | 68,52k | Achat | 17,13 | 139,94k | 2,94% |
| 2026-03-06 | Mr. Brenton L. SaundersCEO & Chairman | 14,70k | 251,96k | Achat | 17,14 | 421,22k | 3,62% |
| 2026-03-06 | Mr. Brenton L. SaundersCEO & Chairman | 727,00 | 12,46k | Achat | 17,10 - 17,16 | 421,22k | 0,17% |
| 2026-03-06 | Mr. A. Robert D. BaileyExec. VP & Chief Legal Officer | 14,60k | 250,34k | Achat | 17,10 - 17,20 | 100,94k | 16,91% |
| 2026-03-06 | Mr. Osama A. EldessoukyExec. VP & CFO | 4,00k | 68,52k | Achat | 17,13 | 139,94k | 2,94% |
| 2026-03-06 | Mr. Brenton L. SaundersCEO & Chairman | 18,79k | 311,04k | Achat | 12,55 - 17,19 | 421,22k | 4,67% |
| 2026-03-03 | Mr. Thomas Warren RossLead Independent Director | 4,50k | 79,56k | Achat | 17,68 | 44,55k | 11,24% |
| 2026-03-03 | Mr. Thomas Warren RossLead Independent Director | 950,00 | 16,79k | Achat | 17,67 | 17,00k | 5,92% |
| 2026-03-02 | Dr. Eduardo C. AlfonsoIndependent Director | 4,30k | 76,97k | Achat | 17,90 | 4,30k | - |
| 2026-02-27 | Dr. Andrew C. von EschenbachIndependent Director | 4,36k | 79,88k | Achat | 18,31 | 46,11k | 10,45% |
| 2026-02-27 | Mr. Osama A. EldessoukyExec. VP & CFO | 113,10k | 2,07M | Derivative Exercise and Retained Stock | 18,30 | 135,94k | 495,14% |
| 2026-02-27 | Mr. Osama A. EldessoukyExec. VP & CFO | -51,47k | 941,90k | Vente | 18,30 | 135,94k | -27,46% |
| 2026-02-27 | Dr. Yehia HashadExec. VP of Research & Development and Chief Medical officer | 47,12k | 862,31k | Derivative Exercise and Retained Stock | 18,30 | 86,47k | 119,77% |
| 2026-02-27 | Dr. Yehia HashadExec. VP of Research & Development and Chief Medical officer | -11,62k | 212,66k | Vente | 18,30 | 86,47k | -11,85% |
| 2026-02-27 | Mr. Frederick J. MunschSenior VP, Controller & CAO | 20,03k | 366,49k | Derivative Exercise and Retained Stock | 18,30 | 39,39k | 103,43% |
| 2026-02-27 | Mr. Frederick J. MunschSenior VP, Controller & CAO | -5,69k | 104,16k | Vente | 18,30 | 39,39k | -12,63% |
| 2026-02-27 | Mr. Luc BonnefoyPresident of Surgical | 16,35k | 299,17k | Derivative Exercise and Retained Stock | 18,30 | 25,41k | 180,40% |
| 2026-02-27 | Mr. Luc BonnefoyPresident of Surgical | -9,22k | 168,74k | Vente | 18,30 | 25,41k | -26,63% |
| 2026-02-27 | Dr. Andrew C. von EschenbachIndependent Director | 4,36k | 79,88k | Achat | 18,31 | 18,56k | 30,74% |
| 2026-03-02 | Dr. Eduardo C. AlfonsoIndependent Director | 4,30k | 76,97k | Achat | 17,90 | 4,30k | - |
| 2026-02-26 | Mr. Frederick J. MunschSenior VP, Controller & CAO | -10,17k | 186,52k | Sale to Issuer | 18,30 - 18,49 | 39,08k | -20,65% |
| 2026-02-26 | Mr. Andrew J. StewartPresident of Global Pharmaceuticals & International Consumer | -4,99k | 91,90k | Sale to Issuer | 18,30 - 18,49 | 25,68k | -16,27% |
| 2026-02-26 | Mr. Luc BonnefoyPresident of Surgical | -17,94k | 329,07k | Sale to Issuer | 18,30 - 18,49 | 28,24k | -38,85% |
| 2026-02-26 | Dr. Yehia HashadExec. VP of Research & Development and Chief Medical officer | -18,87k | 345,64k | Sale to Issuer | 18,30 - 18,49 | 68,16k | -21,68% |
| 2026-02-26 | Mr. Brenton L. SaundersCEO & Chairman | 575,90k | 10,59M | Derivative Exercise and Retained Stock | 18,30 - 18,49 | 406,52k | -340,00% |
| 2026-02-26 | Mr. Brenton L. SaundersCEO & Chairman | -373,66k | 984,20 | Derivative Exercise and Sale | 18,30 - 18,49 | 406,52k | - |
| 2026-02-26 | Mr. A. Robert D. BaileyExec. VP & Chief Legal Officer | 18,84k | 346,75k | Derivative Exercise and Retained Stock | 18,30 - 18,49 | 86,34k | 27,92% |
| 2026-02-26 | Mr. A. Robert D. BaileyExec. VP & Chief Legal Officer | -5,86k | 0,00 | Derivative Exercise and Sale | 18,30 - 18,49 | 86,34k | - |
| 2026-02-26 | Mr. Osama A. EldessoukyExec. VP & CFO | 167,00k | 3,07M | Derivative Exercise and Retained Stock | 18,30 - 18,49 | 74,31k | -180,17% |
| 2026-02-26 | Mr. Osama A. EldessoukyExec. VP & CFO | -121,71k | 14,82 | Derivative Exercise and Sale | 18,30 - 18,49 | 74,31k | - |
| 2026-02-26 | Dr. Yehia HashadExec. VP of Research & Development and Chief Medical officer | 82,80k | 1,52M | Derivative Exercise and Retained Stock | 18,30 - 18,49 | 50,97k | -260,09% |
| 2026-02-26 | Dr. Yehia HashadExec. VP of Research & Development and Chief Medical officer | -38,70k | 58,90 | Derivative Exercise and Sale | 18,30 - 18,49 | 50,97k | - |
| 2026-02-26 | Mr. Frederick J. MunschSenior VP, Controller & CAO | 51,91k | 954,55k | Derivative Exercise and Retained Stock | 18,30 - 18,49 | 25,05k | -193,28% |
| 2026-02-26 | Mr. Frederick J. MunschSenior VP, Controller & CAO | -23,77k | 504,64 | Derivative Exercise and Sale | 18,30 - 18,49 | 25,05k | - |
| 2026-02-26 | Mr. Andrew J. StewartPresident of Global Pharmaceuticals & International Consumer | 67,27k | 1,24M | Derivative Exercise and Retained Stock | 18,30 - 18,49 | 25,68k | -161,74% |
| 2026-02-26 | Mr. Andrew J. StewartPresident of Global Pharmaceuticals & International Consumer | -39,93k | 371,26 | Derivative Exercise and Sale | 18,30 - 18,49 | 25,68k | - |
| 2026-02-27 | Mr. Luc BonnefoyPresident of Surgical | 5,59k | 102,35k | Derivative Exercise and Retained Stock | 18,30 | 18,28k | 44,07% |
| 2026-02-26 | Mr. Luc BonnefoyPresident of Surgical | -19,71k | 44,32k | Derivative Exercise and Sale | 18,30 - 18,49 | 18,28k | - |
| 2026-02-26 | Mr. Luc BonnefoyPresident of Surgical | -1,06k | 19,18k | Vente | 18,30 - 18,49 | 18,28k | -5,48% |
| 2026-02-26 | Mr. A. Robert D. BaileyExec. VP & Chief Legal Officer | -5,86k | 107,81k | Sale to Issuer | 18,30 - 18,49 | 86,34k | -6,35% |
| 2026-02-26 | Mr. Osama A. EldessoukyExec. VP & CFO | -74,04k | 1,36M | Sale to Issuer | 18,30 - 18,49 | 133,67k | -35,65% |
| 2026-02-26 | Mr. Brenton L. SaundersCEO & Chairman | -46,71k | 858,95k | Sale to Issuer | 18,30 - 18,49 | 406,52k | -10,31% |
| 2026-02-23 | Mr. Brenton L. SaundersCEO & Chairman | -65,44k | 1,18M | Sale to Issuer | 17,99 | 334,53k | -16,36% |
| 2026-02-23 | Mr. Brenton L. SaundersCEO & Chairman | 122,06k | 0,00 | Derivative Exercise and Retained Stock | - | 334,53k | 57,44% |
| 2026-02-23 | Mr. Brenton L. SaundersCEO & Chairman | -65,44k | 1,18M | Derivative Exercise and Sale | 17,99 | 334,53k | - |
| 2026-02-23 | Mr. Steven H. CollisIndependent Director | 15,00k | 267,15k | Achat | 17,81 | 15,00k | - |
| 2026-02-20 | Mr. Russel C. RobertsonIndependent Director | 4,40k | 78,76k | Achat | 17,90 | 10,21k | 75,76% |
| 2026-02-23 | Mr. Steven H. CollisIndependent Director | 15,00k | 267,15k | Achat | 17,81 | 15,00k | - |
| 2026-02-20 | Mr. Russel C. RobertsonIndependent Director | 4,40k | 78,76k | Achat | 17,90 | 10,21k | 75,76% |
| 2026-02-19 | Ms. Karen L. LingIndependent Director | 4,00k | 70,97k | Achat | 17,74 | 21,34k | 23,07% |
| 2026-02-19 | Ms. Karen L. LingIndependent Director | 4,00k | 70,97k | Achat | 17,74 | 21,34k | 23,07% |
| 2025-12-09 | Bausch Health Companies Inc.Société | -26,50M | 0,00 | Other Disposition | - | 310,45M | -7,86% |
| 2025-04-02 | Bausch Health Companies Inc.Société | -10,12M | 0,00 | Other Disposition | - | 310,45M | -3,16% |
| 2025-08-05 | Mr. Brenton L. SaundersCEO & Chairman | -4,23k | 61,10k | Sale to Issuer | 14,44 | 399,98k | -1,05% |
| 2025-07-25 | Dr. Yehia HashadExec. VP of Research & Development and Chief Medical officer | -2,84k | 40,68k | Sale to Issuer | 14,32 | 71,63k | -3,82% |
| 2025-07-25 | Mr. Luc BonnefoyPresident of Surgical | -2,17k | 31,03k | Sale to Issuer | 14,32 | 28,77k | -7,00% |
| 2025-07-25 | Mr. Frederick J. MunschSenior VP, Controller & CAO | -1,09k | 15,61k | Sale to Issuer | 14,32 | 36,99k | -2,86% |
| 2025-07-25 | Mr. Osama A. EldessoukyExec. VP & CFO | -4,00k | 57,22k | Sale to Issuer | 14,32 | 171,11k | -2,28% |
| 2025-06-13 | Mr. Luc BonnefoyPresident of Surgical | -968,00 | 11,94k | Sale to Issuer | 12,33 | 30,94k | -3,03% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
